JGC
LRMR icon

J. Goldman & Co’s Larimar Therapeutics LRMR Stock Holding History

J. Goldman & Co’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-135,000
Closed -$436K – 659
2025
Q3 		$436K Buy
+135,000
New +$506K 0.01% 389
2024
Q1 		– Sell
-47,000
Closed -$214K – 469
2023
Q4 		$214K Buy
+47,000
New +$159K 0.01% 297

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

J. Goldman & Co's LRMR Position: Q2 2026 in Review

J. Goldman & Co sold out of Larimar Therapeutics (LRMR) in Q2 2026, closing a stake of 33,756 shares — an estimated $152K sold.

J. Goldman & Co first reported a position in LRMR in Q4 2020 and held it in 12 quarters. The position peaked at $1.55M in Q4 2020. 163 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • J. Goldman & Co reported no remaining Larimar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • J. Goldman & Co sold 33,756 Larimar Therapeutics shares in Q2 2026, an estimated $152K.
  • J. Goldman & Co first reported a position in Larimar Therapeutics in Q4 2020 and held it in 12 quarters.
  • J. Goldman & Co's Larimar Therapeutics position peaked at $1.55M in Q4 2020.
  • 163 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.